ZP 120C (CAS No. 383123-18-0) | Supplied by GMP grade manufacturer

描述

Product Description

Background

ZP 120C (CAS No. 383123-18-0) is a synthetic compound developed as a potent and selective partial agonist of the nociceptin/orphanin FQ receptor (ORL1). This receptor is part of the opioid receptor family but is pharmacologically distinct, often classified as a non-classical opioid receptor due to its structural and functional uniqueness. ORL1 signaling has been linked to a wide array of physiological processes including water and electrolyte homeostasis, cardiovascular regulation, pain modulation, and neuroendocrine balance.

The compound was originally investigated in the context of fluid and electrolyte balance disorders such as hyponatremia (low sodium levels) and hypokalemia (low potassium levels). Hyponatremia is a clinically significant condition often arising from chronic heart failure, liver cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH). Hypokalemia, on the other hand, is common in renal and gastrointestinal disorders as well as in patients under diuretic therapy. ZP 120C’s ability to modulate ORL1 receptor pathways makes it a candidate for studying these electrolyte disorders.

Chemical Properties & Source

• Compound Name: ZP 120C

• CAS Number: 383123-18-0

• Chemical Class: ORL1 receptor agonist (partial agonist)

• Mechanism: ORL1 receptor modulation leading to altered cellular signaling and inhibitory effects on electrically induced smooth muscle contraction.

• Research Use: Electrolyte balance, receptor pharmacology, cardiovascular and renal studies.

Research Significance

The pharmacological activity of ZP 120C represents a unique approach to addressing electrolyte imbalances. Conventional treatments for hyponatremia often involve fluid restriction, hypertonic saline, or vasopressin receptor antagonists. ZP 120C, by targeting ORL1 pathways, provides a distinct non-vasopressin-based mechanism for exploring water and sodium balance. This opens avenues for preclinical models of heart failure and SIADH where hyponatremia remains a therapeutic challenge.

In hypokalemia research, ZP 120C provides a way to study receptor-mediated renal regulation of electrolytes. By inhibiting electrically induced contractions, it also serves as a pharmacological tool for understanding neuromuscular and smooth muscle dynamics in relation to receptor pharmacology.

Comparative Advantages

Compared with other ORL1 agonists such as Ro 64-6198 or nociceptin analogues, ZP 120C demonstrates a partial agonist profile. This makes it less likely to induce complete receptor desensitization while still providing measurable pharmacological effects. Additionally, its effects on electrically induced contraction provide an experimental advantage in tissue-based models where reproducible responses are required.

Product Specifications

Mechanism of Action & Research Applications

Mechanism of Action

ZP 120C functions as a partial agonist at the ORL1 receptor, also known as the nociceptin/orphanin FQ receptor. Activation of ORL1 initiates G-protein coupled receptor signaling cascades, typically involving Gi/o proteins. The downstream effects include:

• Inhibition of adenylate cyclase ? reduced intracellular cAMP levels

• Activation of potassium channels ? hyperpolarization of neurons and smooth muscle cells

• Inhibition of calcium channel currents ? reduced neurotransmitter release and contractile activity

In experimental systems, ZP 120C demonstrates inhibition of electrically induced contractions, indicating its modulatory effect on neuromuscular and smooth muscle responses.

Research Applications

1. Hyponatremia Models – Understanding sodium imbalance regulation via ORL1 modulation.

2. Hypokalemia Research – Exploring renal and systemic potassium regulation under ORL1 pathway influence.

3. Receptor Pharmacology – Characterization of ORL1 receptor binding, signaling, and partial agonist activity.

4. Cardiovascular Models – Studying vascular smooth muscle responses under ORL1 receptor activation.

5. Neuroendocrine Regulation – Investigating ORL1 receptor involvement in hypothalamic-pituitary-adrenal (HPA) axis.

6. Electrophysiology Studies – Using electrically induced contraction models to dissect receptor-mediated inhibition.

7. Comparative Agonist Analysis – Evaluating differences between full and partial ORL1 agonists.

   

Side Effects (For Reference in Research Models)

• Neurological Effects: Partial agonists at ORL1 receptors may modulate pain perception, mood, and reward pathways.

• Electrolyte Modulation: Altered sodium and potassium balance could result in unexpected outcomes depending on experimental design.

• Cardiovascular: Potential impact on vascular tone and cardiac output in animal models.

• CNS Depression: Possible sedative-like effects at higher concentrations.

• Solvent-related Artifacts: Use of DMSO or ethanol in dissolving ZP 120C may cause independent effects in cell culture or tissue assays.

Disclaimer

For laboratory research use only. Not for human use, clinical treatment, or veterinary applications.

Keywords

•  CAS 383123-18-0

•  ORL1 receptor agonist

• ZP 120C hyponatremia research

• ZP 120C hypokalemia studies

• ORL1 receptor partial agonist

• Nociceptin receptor pharmacology

• Smooth muscle contraction inhibitor ZP 120C

• GMP-grade ZP 120C supplier

• ZP 120C drug discovery research